R&D

After 20 years of research, our scientists were the first to cultivate the patented micro-organism strain Irpex lacteus fk. The identified strain was isolated and deposited with the international patent microorganism depository institution: the Microbial Bank of the National Agricultural Science Institute in Korea in 2021.

In early 2022, we obtained a patent for the invention and utilization of metabolite EFILA derived from this strain for the prevention and treatment of disease.

EFILA is a patented strain cultivated from medicinal mushroom strains found on pine trees and is 100% natural.

Through clinical studies, EFILA has been proven to have significant positive impacts on the prevention and treatment of diabetes and liver diseases. Users have also reported positive effects on the eyes, skin, and sleep. Efila can prevent aging in all aspects of the human body.

Our team of scientists in Korea has stabilized the strain cultivation process, and the active substance yield has increased from the 20% initially to 100% today. We have also developed a factory manufacturing process that has reached a stable level for large-scale production. We will continue to research upon the preventive and therapeutic effects of Irpex lacteus fk and EFILA on liver diseases,
as well as explore its potential in anti-aging research.